Many medications used in older adults have strong anticholinergic (ACH) properties, which may increase the risk of falls and fractures. Use of these medications was identified in a population-based Canadian cohort.
Objective
To identify the fall and fracture risk associated with ACH medication use.
Methods
Data collection and analysis were conducted at baseline, year 5, and year 10. Cross-sectional analyses were performed to examine associations between ACH medication use and falls. Time-dependent Cox regression was used to examine time to first nontraumatic fracture. Finally, change in bone mineral density (BMD) over 10 years was compared in ACH medication users versus nonusers.
Results
Strongly ACH medications were used by 618 of 7753 participants (8.0%) at study baseline, 592 (9.5%) at year 5, and 334 (7.7%) at year 10. Unadjusted ACH medication use was associated with falls at baseline (odds ratio = 1.50; 95% CI = 1.14-1.98; P = 0.004), but the association was no longer significant after covariate adjustment. Similar results occurred at years 5 and 10. ACH medication use was associated with increased incident fracture risk before (hazard ratio = 1.22; CI = 1.13-1.32; P < 0.001) but not after covariate adjustment. Mean (SD) change in femoral neck BMD T-score over 10 years, in those using ACH medications at both years 0 and 5, was -0.60 (0.63) in ACH users versus -0.49 (0.45) in nonusers (P = 0.041), but this was not significant after covariate adjustment.
Conclusions
ACH medications were not found to be independently associated with an increased risk of falling, fractures, or BMD loss. Rather, factors associated with ACH medication use explained the apparent associations.
anticholinergic medications fall risk, anticholinergic fracture bone mineral density, medication-related falls older adults, anticholinergic burden fracture risk, 10-year cohort anticholinergic medications, Canadian population-based fall study, polypharmacy fracture risk elderly, medication safety bone health, drug-induced falls osteoporosis
PMID 24816210 24816210 DOI 10.1177/1060028014535363 10.1177/1060028014535363
Cite this article
Fraser, L. A., Adachi, J. D., Leslie, W. D., Goltzman, D., Josse, R., Prior, J., Kaiser, S., Kreiger, N., Kovacs, C. S., Anastassiades, T. P., Papaioannou, A., & for the CaMos Research Group (2014). Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period. *The Annals of pharmacotherapy*, *48*(8), 954-961. https://doi.org/10.1177/1060028014535363
Fraser LA, Adachi JD, Leslie WD, Goltzman D, Josse R, Prior J, et al. Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period. Ann Pharmacother. 2014;48(8):954-961. doi:10.1177/1060028014535363
Fraser, L. A., et al. "Effect of Anticholinergic Medications on Falls, Fracture Risk, and Bone Mineral Density Over a 10-Year Period." *The Annals of pharmacotherapy*, vol. 48, no. 8, 2014, pp. 954-961.
We used data from a large, prospective Canadian cohort to assess the association between selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs) and...
Nguyen S et al., 2013American Journal of Public Health
OBJECTIVES: Increasing 25-hydroxyvitamin D serum levels can prevent a wide range of diseases. There is a concern about increasing kidney stone risk with vitamin D supplementation. We used GrassrootsHe...
Although low bone mineral density (BMD) predicts fractures, there are postulated sex differences in the fracture "threshold." Some studies demonstrate a higher mean BMD for men with fractures than for...
Curcumin, a bioactive polyphenol derived from turmeric (Curcuma longa), has garnered substantial attention for its potent anti-inflammatory, antioxidant, and antineoplastic properties. This review exp...